Canagliflozin, an SGLT2 inhibitor, corrects glycemic dysregulation in TallyHO model of T2D but only partially prevents bone deficits.

MLA

Thrailkill, Kathryn M., et al. “Canagliflozin, an SGLT2 Inhibitor, Corrects Glycemic Dysregulation in TallyHO Model of T2D but Only Partially Prevents Bone Deficits.” Bone, vol. 141, Dec. 2020, p. 115625. EBSCOhost, https://doi.org/10.1016/j.bone.2020.115625.

APA

Thrailkill, K. M., Bunn, R. C., Uppuganti, S., Ray, P., Popescu, I., Kalaitzoglou, E., Fowlkes, J. L., & Nyman, J. S. (2020). Canagliflozin, an SGLT2 inhibitor, corrects glycemic dysregulation in TallyHO model of T2D but only partially prevents bone deficits. Bone, 141, 115625. https://doi.org/10.1016/j.bone.2020.115625

Chicago

Thrailkill, Kathryn M, R Clay Bunn, Sasidhar Uppuganti, Philip Ray, Iuliana Popescu, Evangelia Kalaitzoglou, John L Fowlkes, and Jeffry S Nyman. 2020. “Canagliflozin, an SGLT2 Inhibitor, Corrects Glycemic Dysregulation in TallyHO Model of T2D but Only Partially Prevents Bone Deficits.” Bone 141 (December): 115625. doi:10.1016/j.bone.2020.115625.